Stocktoria
NovaBridge Biosciences NBP
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-01-17
NovaBridge Biosciences financials (annual)
Bars are annual figures from 2018 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $632,000 | -$1.6M | $88.0M | $1.5B | $4.3M | $53.8M |
| R&D expense | $62.9M | $21.8M | $21.4M | $22.5M | $190.3M | $150.9M | $120.7M | $426.0M |
| Operating income | -$94.3M | -$51.4M | -$72.0M | -$53.1M | — | — | — | — |
| Interest expense | — | — | $102,000 | $1,000 | $0 | $147,000 | $430,000 | $11.7M |
| Income tax | $0 | $0 | $0 | $103,000 | -$495,000 | $1.9M | $0 | $1.7M |
| Net income | -$46.3M | -$22.2M | -$207.7M | -$371.1M | -$365.9M | $72.2M | -$208.6M | -$402.8M |
| EPS (diluted) | $-0.21 | $-0.12 | $-1.09 | $-1.96 | $-2.09 | $0.46 | $-28.90 | $-61.70 |
| Operating cash flow | -$20.6M | -$52.7M | -$183.8M | -$159.9M | -$152.7M | $66.4M | -$124.7M | -$280.7M |
| Free cash flow | -$20.6M | -$52.7M | -$184.0M | -$162.0M | -$157.4M | $65.2M | -$126.4M | -$295.1M |
| Cash & equivalents | $210.6M | $68.3M | $291.5M | $342.9M | $552.9M | $729.3M | $163.4M | $1.6B |
| Inventory | — | — | — | $0 | $4.3M | $0 | — | — |
| Total assets | $260.5M | $212.7M | $368.9M | $590.6M | $878.9M | $970.7M | $249.6M | $2.4B |
| Total liabilities | $29.6M | $11.5M | $126.3M | $168.7M | $163.5M | $108.3M | $96.0M | $415.7M |
| Shareholders' equity | $230.9M | $201.2M | $242.6M | $417.8M | $715.1M | $862.4M | -$292.3M | -$955.1M |
Growth · year-over-year · Revenue CAGR -58.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | -101.8% | -94.3% | +35701.1% | -92.0% | — |
| Net income growth | — | — | — | — | -607.0% | — | — | — |
| EPS growth | — | — | — | — | -554.3% | — | — | — |
| Free cash flow growth | — | — | — | — | -341.3% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.